Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

[1]  D. Lowy,et al.  HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. , 2011, Vaccine.

[2]  S. Franceschi,et al.  Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication , 2011, International journal of cancer.

[3]  N. Muñoz,et al.  Incident Cervical HPV Infections in Young Women: Transition Probabilities for CIN and Infection Clearance , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[4]  N. Muñoz,et al.  Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. , 2010, The Lancet. Oncology.

[5]  T. Iftner,et al.  Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. , 2010, Journal of the National Cancer Institute.

[6]  Joakim Dillner,et al.  Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. , 2010, Journal of the National Cancer Institute.

[7]  S. Wacholder,et al.  Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants , 2009, International journal of cancer.

[8]  B Romanowski,et al.  Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women , 2009, The Lancet.

[9]  P. Coursaget,et al.  Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications , 2009, Protein science : a publication of the Protein Society.

[10]  M. Schiffman,et al.  Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline , 2009, Infectious Agents and Cancer.

[11]  K. Straif,et al.  A review of human carcinogens--Part B: biological agents. , 2009, The Lancet. Oncology.

[12]  C. Wheeler,et al.  Human Papillomavirus Genotype Distributions: Implications for Vaccination and Cancer Screening in the United States , 2009, Journal of the National Cancer Institute.

[13]  C. Wheeler,et al.  The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. , 2009, The Journal of infectious diseases.

[14]  R. DeSalle,et al.  Evolutionary Dynamics of Variant Genomes of Human Papillomavirus Types 18, 45, and 97 , 2008, Journal of Virology.

[15]  Diane Solomon,et al.  Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. , 2008, Vaccine.

[16]  F. X. Bosch,et al.  Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. , 2008, Vaccine.

[17]  C. Poole,et al.  Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. , 2008, American journal of epidemiology.

[18]  V. Wong,et al.  All that palsies is not Bell's -the need to define Bell's palsy as an adverse event following immunization. , 2007, Vaccine.

[19]  M. Klein,et al.  Crystal Structures of Four Types of Human Papillomavirus L1 Capsid Proteins , 2007, Journal of Biological Chemistry.

[20]  Martha J. Brown,et al.  Antibodies from Women Immunized with Gardasil ® Cross-Neutralize HPV 45 Pseudovirions , 2007, Human vaccines.

[21]  Henry C Kitchener,et al.  Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial , 2007, The Lancet.

[22]  J. Dillner,et al.  Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles. , 2007, The Journal of general virology.

[23]  R. Zuna,et al.  Distribution of HPV genotypes in 282 women with cervical lesions: evidence for three categories of intraepithelial lesions based on morphology and HPV type , 2007, Modern Pathology.

[24]  H. Selinka,et al.  Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33 , 2006, Virology Journal.

[25]  W. Quint,et al.  Highly Effective Detection of Human Papillomavirus 16 and 18 DNA by a Testing Algorithm Combining Broad-Spectrum and Type-Specific PCR , 2006, Journal of Clinical Microbiology.

[26]  M. Lehtinen,et al.  Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing , 2006, International journal of STD & AIDS.

[27]  J. Berkhof,et al.  Prevalence of types 16 and 33 is increased in high‐risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse , 2005, International journal of cancer.

[28]  R. DeSalle,et al.  The carcinogenicity of human papillomavirus types reflects viral evolution. , 2005, Virology.

[29]  S. Franceschi,et al.  Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis , 2003, British Journal of Cancer.

[30]  F. X. Bosch,et al.  Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.

[31]  P. Coursaget,et al.  Identification of Two Cross-Neutralizing Linear Epitopes within the L1 Major Capsid Protein of Human Papillomaviruses , 2002, Journal of Virology.

[32]  N. Christensen,et al.  Immunological analyses of human papillomavirus capsids. , 2001, Vaccine.

[33]  C. Key,et al.  The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study. , 2000, Gynecologic oncology.

[34]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[35]  R. Burk,et al.  Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. , 1995, Journal of the National Cancer Institute.

[36]  David R. Scott,et al.  Persistence of type-specific human papillomavirus infection among cytologically normal women. , 1994, The Journal of infectious diseases.

[37]  C. Wheeler,et al.  Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. , 2012, The Lancet. Oncology.

[38]  Magnus von Knebel Doeberitz,et al.  Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. , 2008, Cancer research.